April 6, 2024
Empagliflozin after Acute Myocardial Infarction
Key Points
Key points are not available for this paper at this time.
Abstract
Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Javed Butler
Heart Failure & Transplant
W
W. Schuyler Jones
Interventional Cardiology
J
Jacob A. Udell
Preventive Cardiology
Journals
New England Journal of Medicine
Actions
Institutions
Duke Medical Center
Duke University Hospital
Clinical Research Institute
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...